Molecular and Clinical Activity of CDX-3379, an Anti-ErbB3 Monoclonal Antibody, in Head and Neck Squamous Cell Carcinoma.

CONCLUSIONS: This study demonstrates that CDX-3379 can inhibit tumor ErbB3 phosphorylation in HNSCC. CDX-3379 was well tolerated and associated with measurable tumor regression. A phase 2 study (NCT03254927) has been initiated to evaluate CDX-3379 in combination with cetuximab for patients with advanced HNSCC. PMID: 31308059 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/31308059?dopt=Abstract

Source: Clinical Cancer Research - July 14, 2019 Category: Cancer & Oncology Authors: Duvvuri U, George J, Kim S, Alvarado D, Neumeister VM, Chenna A, Gedrich R, Hawthorne T, LaVallee T, Grandis JR, Bauman JE Tags: Clin Cancer Res Source Type: research